Mark Stenhouse

Mar 20, 2018

Exact Sciences has appointed Mark Stenhouse to the new role of president for its flagship product Cologuard, a non-invasive stool-based DNA test for early detection of colorectal cancer. Stenhouse, who is currently serving as vice president of the US immunology group at AbbVie, will assume this new position on April 2. At AbbVie, Stenhouse leads the sales and marketing teams for the anti-inflammatory drug Humira. He has spent nearly 30 years at Abbott Laboratories/AbbVie, where he was first hired for a field sales position. He became national sales director in the US immunology-gastroenterology franchise, and rose to marketing director, followed by senior director of commercial initiatives. In 2010, Stenhouse was appointed a general manager within the company before being promoted to vice president.

More Like This

Jan 22, 2019

Michael Rasche

Metabolon has appointed Michael Rasche as its president of international business. Rasche will lead the firm's international business activities with a focus on customer and team expansion. Prior to Metabolon, Rasche acted as chief commercial officer at Definiens. Before Definiens, Rasche served as corporate VP of global commercial operations at Ayoxxa. He has also held leadership positions at Dako (now Agilent), Roche, and Bayer Diagnostics in Europe, as well as North and South America. 

Jan 18, 2019

TJ Johnson, John Lubniewski

HTG Molecular Diagnostics has announced that TJ Johnson, the firm's current CEO, will assume the role of executive chairman of its board of directors. John Lubniewski, HTG's president and chief operating officer, will succeed Johnson as CEO. In addition, Ann Hanham will assume the role of lead independent director at the end of Q1 2019.

Lubniewski has served as HTG's president and COO since April 2018, joining the firm in 2011 as chief business officer. Before HTG, Lubniewski served in several leadership roles at Ventana, including senior VP and life cycle leader for platforms and clinical assays, as well as head of global marketing. Prior to Ventana, Lubniewski worked at Corning for over a decade in a variety of roles.

Jan 17, 2019

Deanna Church

Deanna Church has joined gene editing technology company Inscripta as senior director of mammalian applications. Previously, she was senior director of applications at 10x Genomics, and before that, senior director of genomics and content at Personalis. Prior to that, she was a staff scientist at the National Center for Biotechnology Information. Church holds a PhD in genomics, genetics, and molecular biology from the University of California, Irvine, and a BA in liberal arts from the University of Virginia.

Jan 14, 2019

Jonathan Jaglom, Gil Ronen

NRGene said this week that it has appointed Jonathan Jaglom as the firm's CEO. Jaglom succeeds NRGene's cofounder Gil Ronen, who has transitioned to the firm's president. Jaglom previously served as NRGene's chief operating officer. Prior to joining NRGene in 2018, Jaglom served as CEO of MakerBot. He has also held executive roles at Stratasys, including general manager and VP of sales operations. 

Jan 09, 2019

William Finger

Cancer Genetics has appointed William Finger as its executive VP of precision medicine and biopharma solutions. He will be responsible for developing and overseeing the company's precision medicine and biopharma and clinical trial business unit. Finger has more than 25 years of experience in the life sciences, diagnostics, and lab service industries. Before joining Cancer Genetics, he acted as managing director of precision medicine and diagnostics for Kineticos, a life science consultancy firm. Before Kineticos, Finger spent 12 years at Laboratory Corporation of America, where he held leadership positions in scientific affairs, preclinical services, biorepository, and operations.

Jan 08, 2019

Richard Compton

Richard Compton resigned as director of Metrichor, a sister company of Oxford Nanopore Technologies, last month. He was appointed to the firm's board in 2016 and was also general manager at Metrichor. Compton remains VP of commercial operations at Oxford Nanopore. He previously served as VP and general manager of the EMEA region at Illumina.

Jan 08, 2019

Ian Heynen

Ian Heynen has been named general manager of Sysmex Canada, a wholly owned subsidiary of Sysmex America. He will execute the firm's business strategy in the Canadian market and will report to Sysmex Canada CEO Andy Hay. Heynen was most recetly senior vice president of sales and marketing for Profound Medical. Prior to that he was acting president of the international division of Hologic. 

Jan 07, 2019

Samar Parikh

Binx Health has appointed Samar Parikh to its board of directors. Parikh has held various leadership positions at Amazon including global leader business development and strategy, and general manager CPG, consumer healthcare, and consumer healthcare innovation. Boston-based Binx is developing a desktop point-of-care platform called Io to perform rapid PCR-based detection in 30 minutes and with laboratory quality results. A multicenter, clinical study is currently underway to evaluate Io for clearance from the US Food and Drug Administration for chlamydia and gonorrhea. 

Jan 07, 2019

Cara Williams

Cara Williams has joined the scientific advisory board of data science company Genialis. She is vice president and head of immunology and respiratory disease research Germany at Boehringer Ingelheim. Prior to that, she was senior director of inflammation and remodeling research at Pfizer. Williams holds a PhD from Liverpool University.

Jan 07, 2019

Cindy Perettie

Foundation Medicine, a Roche company, has appointed Cindy Perettie as its CEO effective Feb. 4, replacing Troy Cox. Most recently, Perettie served as senior VP in global oncology product strategy at Roche's oncology unit. Prior to Roche, she acted as president of global development innovations at the Sarah Cannon Research Institute. Perettie has also held a number of positions at Genentech, also a unit of Roche, including VP of global regulatory operations and regional head of Europe, Middle East, and Africa operations and global development.

Jan 07, 2019

Jon Cohen, Geoff Monk

Jon Cohen has been appointed as executive chairman of BioReference Laboratories, a unit of Opko Health.

Most recently, he was senior vice president and group executive for diagnostic solutions at Quest Diagnostics. Prior to that, he was a managing director for health industries services at PricewaterhouseCoopers, and before that, chief medical officer at North Shore-Long Island Jewish Health System. Cohen holds a BS degree from the University of Miami and an MD degree from the University of Miami School of Medicine.

OpkoHealth has also promoted Geoff Monk to president of BioReference Laboratories. He joined the company last year as general manager.

Jan 04, 2019

Paul Meister

Arbor Biotechnologies has appointed Paul Meister to its board of directors. Meister serves as CEO of Liberty Lane Partners and previously served as president of MacAndrews & Forbes, CEO of inVentiv Health (now known as Syneos Health), and chairman of the board of Thermo Fisher Scientific and vice chairman of Fisher Scientific International, prior to Fisher's merger with Thermo.

Jan 04, 2019

Christine Tsingos

Christine Tsingos intends to retire as Executive Vice President and Chief Financial Officer of Bio-Rad, effective April 30, 2019. She has served as CFO for 16 years, during which time the company increased its revenues more than 240 percent and saw an appreciation in its stock price from approximately $30 to a recent high of more than $300 per share. Tsingos will remain in her current role through April 30, and will assist in the transition to a successor.

Jan 03, 2019

Clinton Musil

Clinton Musil has been appointed as chief business officer of Personalis, where he will initially focus on financing strategy. He joins the company from ARMO Biosciences. Prior to that, he was a managing director at Hercules Capital. Musil holds an MBA from Harvard Business School and a BS in molecular and cellular biology from the University of Arizona.

Jan 03, 2019

James Angus McDonald, Tim Cowper

James Angus McDonald has left the board of directors of Oxford Nanopore Technologies as well as the board of its daughter companies, the Genome Foundry and Metrichor, effective Dec. 13, 2018. He had been a director for Oxford Nanopore since 2010, for Metrichor since 2013, and for the Genome Foundry since 2015. McDonald was immediately replaced as director of all three companies by Tim Cowper, Oxford Nanopore's vice president of finance. Cowper joined the firm in 2012 and oversees its financial team and strategic supply chain operations. In addition, in November 2018, he was appointed as director of Oxford Nanopore Manufacturing, a new daughter company.

John Mendelsohn, a former president of the University of Texas MD Anderson Cancer Center, has died, the New York Times reports.

Chinese state news agency Xinhua reports that a preliminary investigation has found He Jiankui performed his gene-editing work illegally.

Identical twins receive different estimates of ancestry from the same direct-to-consumer genetic testing firms, CBC reports.

In PNAS this week: chromosomal features of maize, adaptations in the vinous-throated parrotbill, and more.